A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Markov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Short-term Prognosis After Emergency Department Diagnosis of TIA
Johnston, S. C. (2000) · JAMA · doi:10.1001/jama.284.22.2901 · Cited by 1,300
Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel Disease
Serruys, P. W., Unger, F., Sousa, J. E., Jatene, A., Bonnier, H. J. R. M., Schönberger, J. P. A. M., Buller, N., Bonser, R., van den Brand, M. J. B., van Herwerden, L. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441502 · Cited by 1,114
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
Coronary heart disease statistics.
Allender, S. E., Peto, V., Scarborough, P., Kaur, A., & Rayner, M. (2008) · Deakin Research Online (Deakin University) · Cited by 928
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
(1995) · The Lancet · doi:10.1016/s0140-6736(95)92836-7 · Cited by 856
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 842
Transient Ischemic Attack — Proposal for a New Definition
Albers, G. W., Caplan, L. R., Easton, J. D., Fayad, P. B., Mohr, J. P., Saver, J. L., & Sherman, D. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmsb020987 · Cited by 840
National service framework for coronary heart disease
Lloyd-Mostyn, R. (2000) · BMJ · doi:10.1136/bmj.321.7261.634 · Cited by 832
Jialal, I., Stein, D., Balis, D., Grundy, S. M., Adams-Huet, B., & Devaraj, S. (2001) · Circulation · doi:10.1161/01.cir.103.15.1933 · Cited by 730
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
Jacobs, D., Blackburn, H., Higgins, M., Reed, D., Iso, H., McMillan, G., Neaton, J., Nelson, J., Potter, J., & Rifkind, B. (1992) · Circulation · doi:10.1161/01.cir.86.3.1046 · Cited by 720
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 719
Ballantyne, C. M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L. J., Suresh, R., Sun, S., LeBeaut, A. P., Sager, P. T., & Veltri, E. P. (2003) · Circulation · doi:10.1161/01.cir.0000068312.21969.c8 · Cited by 687
Wiegman, A., Hutten, B. A., de Groot, E., Rodenburg, J., Bakker, H. D., Büller, H. R., Sijbrands, E. J. G., & Kastelein, J. J. P. (2004) · JAMA · doi:10.1001/jama.292.3.331 · Cited by 649
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 609
Primary and subsequent coronary risk appraisal: New results from the Framingham study
D'Agostino, R. B., Russell, M. W., Huse, D. M., Ellison, R. C., Silbershatz, H., Wilson, P. W. F., & Hartz, S. C. (2000) · American Heart Journal · doi:10.1016/s0002-8703(00)90236-9 · Cited by 589
Taylor, A. J., Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Vernalis, M. N. (2002) · Circulation · doi:10.1161/01.cir.0000034508.55617.65 · Cited by 558
Okazaki, S., Yokoyama, T., Miyauchi, K., Shimada, K., Kurata, T., Sato, H., & Daida, H. (2004) · Circulation · doi:10.1161/01.cir.0000140261.58966.a4 · Cited by 553
Athyros, V. G., Papageorgiou, A. A., Mercouris, B. R., Athyrou, V. V., Symeonidis, A. N., Basayannis, E. O., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000787 · Cited by 533
Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study
Brindle, P., Jonathan, E., Lampe, F., Walker, M., Whincup, P., Fahey, T., & Ebrahim, S. (2003) · BMJ · doi:10.1136/bmj.327.7426.1267 · Cited by 525
Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
Clarke, P., Gray, A., & Holman, R. (2002) · Medical Decision Making · doi:10.1177/027298902400448902 · Cited by 515
Nawrocki, J. W., Weiss, S. R., Davidson, M. H., Sprecher, D. L., Schwartz, S. L., Lupien, P.-J., Jones, P. H., Haber, H. E., & Black, D. M. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.678 · Cited by 484
Mohler, E. R., Hiatt, W. R., & Creager, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000090686.57897.f5 · Cited by 479
Total cholesterol and risk of mortality in the oldest old
Weverling-Rijnsburger, A. W., Blauw, G. J., Lagaay, A. M., Knock, D. L., Meinders, A. E., & Westendorp, R. G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04430-9 · Cited by 474
Pedersen, T. R., Kjekshus, J., Pyörälä, K., Olsson, A. G., Cook, T. J., Musliner, T. A., Tobert, J. A., & Haghfelt, T. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00904-1 · Cited by 466
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 449
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444
Haffner, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2661 · Cited by 441
Pitt, B., Mancini, G. B. J., Ellis, S. G., Rosman, H. S., Park, J.-S., & Mcgovern, M. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00301-0 · Cited by 429
Cholesterol lowering and mortality: the importance of considering initial level of risk.
Smith, G. D., Song, F., & Sheldon, T. A. (1993) · BMJ · doi:10.1136/bmj.306.6889.1367 · Cited by 423
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 421
A review of the use of health status measures in economic evaluation.
Brazier, Deverill, Green, Harper, & Booth (1999) · Health Technology Assessment · doi:10.3310/hta3090 · Cited by 413
Bakker-Arkema, R. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530260042029 · Cited by 407
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
The rational clinical examination. Is this patient taking the treatment as prescribed?
Stephenson, B. J. (1993) · JAMA · doi:10.1001/jama.269.21.2779 · Cited by 387
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Very Early Risk of Stroke After a First Transient Ischemic Attack
Lovett, J. K., Dennis, M. S., Sandercock, P. A. G., Bamford, J., Warlow, C. P., & Rothwell, P. M. (2003) · Stroke · doi:10.1161/01.str.0000080935.01264.91 · Cited by 366
Rao, S., Porter, D. C., Chen, X., Herliczek, T., Lowe, M., & Keyomarsi, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7797 · Cited by 345
Mark, D. B., Naylor, C. D., Hlatky, M. A., Califf, R. M., Topol, E. J., Granger, C. B., Knight, J. D., Nelson, C. L., Lee, K. L., Clapp-Channing, N. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410273311706 · Cited by 344
Pepine, C. J., Cohn, P. F., Deedwania, P. C., Gibson, R. S., Handberg, E., Hill, J. A., Miller, E., Marks, R. G., & Thadani, U. (1994) · Circulation · doi:10.1161/01.cir.90.2.762 · Cited by 339
Pravastatin Therapy and the Risk of Stroke
White, H. D., Simes, R. J., Anderson, N. E., Hankey, G. J., Watson, J. D. G., Hunt, D., Colquhoun, D. M., Glasziou, P., MacMahon, S., Kirby, A. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430502 · Cited by 338
Should there be a moratorium on the use of cholesterol lowering drugs?
Davey Smith, G., & Pekkanen, J. (1992) · BMJ · doi:10.1136/bmj.304.6824.431 · Cited by 333
Strandberg, T. E., Pyörälä, K., Cook, T. J., Wilhelmsen, L., Faergeman, O., Thorgeirsson, G., Pedersen, T. R., & Kjekshus, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 331
Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future Needs
Brewer, T., & Colditz, G. A. (1999) · JAMA · doi:10.1001/jama.281.9.824 · Cited by 327
Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project.
Dennis, M., Bamford, J., Sandercock, P., & Warlow, C. (1990) · Stroke · doi:10.1161/01.str.21.6.848 · Cited by 320
Ferrier, K. E., Muhlmann, M. H., Baguet, J.-P., Cameron, J. D., Jennings, G. L., Dart, A. M., & Kingwell, B. A. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01717-5 · Cited by 317
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313
Wei, L., Wang, J., Thompson, P., Wong, S., Struthers, A. D., & MacDonald, T. M. (2002) · Heart · doi:10.1136/heart.88.3.229 · Cited by 292
Pedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.18.2085 · Cited by 286
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
Goodacre, S. (2004) · BMJ · doi:10.1136/bmj.37956.664236.ee · Cited by 270
Statins and risk of polyneuropathy: A case-control study
Gaist, D., Jeppesen, U., Andersen, M., García Rodríguez, L. A., Hallas, J., & Sindrup, S. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1333 · Cited by 270
McCrindle, B. W., Ose, L., & Marais, A. D. (2003) · The Journal of Pediatrics · doi:10.1016/s0022-3476(03)00186-0 · Cited by 269
Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., Pastore, M., Borrello, F., Belcastro, M., Picchi, A., et al. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00010-x · Cited by 266
Empana, J. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.09.002 · Cited by 263
Serruys, P. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1150 · Cited by 259
Mercuri, M., Bond, M. G., Sirtori, C. R., Veglia, F., Crepaldi, G., Saverio Feruglio, F., Descovich, G., Ricci, G., Rubba, P., Mancini, M., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00333-6 · Cited by 253
Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
Prosser, L. A., Stinnett, A. A., Goldman, P. A., Williams, L. W., Hunink, M. G. M., Goldman, L., & Weinstein, M. C. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00002 · Cited by 249
Clarke, P., Gray, A., Legood, R., Briggs, A., & Holman, R. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00972.x · Cited by 246
Davidson, M., McKenney, J., Stein, E., Schrott, H., Bakker-Arkena, R., Fayyad, R., & Black, D. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00174-4 · Cited by 233
Davidson, M., Ma, P., Stein, E. A., Gotto, A. M., Raza, A., Chitra, R., & Hutchinson, H. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02226-3 · Cited by 230
Colhoun, H. M., Betteridge, D. J., & Durrington, P. N. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.10.017 · Cited by 229
Wolfe, C. D. A. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.211 · Cited by 229
Dargie, H. J., Ford, I., Fox, K. M., & on behalf of the TIBET study group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014668 · Cited by 229
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
Postmarketing Surveillance—Lack of Vigilance, Lack of Trust
Fontanarosa, P. B. (2004) · JAMA · doi:10.1001/jama.292.21.2647 · Cited by 221
Reductase Inhibitor Monotherapy and Stroke Prevention
Crouse, J. R. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.12.1305 · Cited by 221
Rehnqvist, N., Hjemdahl, P., Billing, E., Bjorkander, I., Eriksson, S. V., Forslund, L., Held, C., Nasman, P., & Wallen, N. H. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014695 · Cited by 220
The European Journal of Cardiovascular Nursing
Jaarsma, T., Fridlund, B., Strőmberg, A., & Thompson, D. R. (2009) · European Journal of Cardiovascular Nursing · doi:10.1016/j.ejcnurse.2009.01.003 · Cited by 218
Haq, I. U., Ramsay, L. E., Yeo, W. W., Jackson, P. R., & Wallis, E. J. (1999) · Heart · doi:10.1136/hrt.81.1.40 · Cited by 215
Self-citationWarlow, C. P. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301381 · Cited by 211
Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study
Gaist, D., Alberto García Rodríguez, L., Huerta, C., Hallas, J., & Sindrup, S. H. (2001) · Epidemiology · doi:10.1097/00001648-200109000-00017 · Cited by 210
A Meta-Analysis of Quality-of-Life Estimates for Stroke
Tengs, T. O., & Lin, T. H. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321030-00004 · Cited by 210
Bypass angioplasty revascularization investigation.
Madias, J. E. (1997) · PubMed · Cited by 209
Tan, K. C. B. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.563 · Cited by 206
Caro, J., Klittich, W., McGuire, A., Ford, I., Norrie, J., Pettitt, D., McMurray, J., & Shepherd, J. (1997) · BMJ · doi:10.1136/bmj.315.7122.1577 · Cited by 203
Waters, D. D., Guyton, J. R., Herrington, D. M., McGowan, M. P., Wenger, N. K., & Shear, C. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.031 · Cited by 201
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
von Haehling, S., & Anker, S. D. (2005) · Heart · doi:10.1136/hrt.2004.042515 · Cited by 200
Incidence of transient ischemic attacks in Oxfordshire, England.
Dennis, M. S., Bamford, J. M., Sandercock, P. A., & Warlow, C. P. (1989) · Stroke · doi:10.1161/01.str.20.3.333 · Cited by 198
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
Olsson, A. G., Pears, J., McKellar, J., Mizan, J., & Raza, A. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01727-1 · Cited by 193
Aronow, W. S., Nayak, D., Woodworth, S., & Ahn, C. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00833-6 · Cited by 191
Dart, A., Jerums, G., Nicholson, G., d'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 187
(2003) · Cerebrovascular Diseases · doi:10.1159/000072562 · Cited by 184
(1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90858-a · Cited by 182
Management of peripheral arterial disease in primary care
Burns, P., Gough, S., & Bradbury, A. W. (2003) · BMJ · doi:10.1136/bmj.326.7389.584 · Cited by 179
Sheridan, S., Pignone, M., & Mulrow, C. (2003) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2003.30107.x · Cited by 178
Andrews, T. C., Ballantyne, C. M., Hsia, J. A., & Kramer, J. H. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00799-9 · Cited by 177
Olsson, A. G., Istad, H., Luurila, O., Ose, L., Stender, S., Tuomilehto, J., Wiklund, O., Southworth, H., Pears, J., & Wilpshaar, J. W. (2002) · American Heart Journal · doi:10.1067/mhj.2002.128049 · Cited by 177
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
Hunninghake, D. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00437-3 · Cited by 176
Jonsson, B., Johannesson, M., Kjekshus, J., Olsson, A. G., Pedersen, T. R., Wedel, H., & Scandlnavlan Simvastatin Survival Study Group (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014994 · Cited by 176
Pharoah, P. D. P., & Hollingworth, W. (1996) · BMJ · doi:10.1136/bmj.312.7044.1443 · Cited by 168
Brown, G. C. (2004) · Evidence-Based Eye Care · doi:10.1097/01.ieb.0000142773.91809.e5 · Cited by 165
Schuster, H., Barter, P. J., Stender, S., Cheung, R. C., Bonnet, J., Morrell, J. M., Watkins, C., Kallend, D., & Raza, A. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.004 · Cited by 160
Nissen, S. E., Tuzcu, E. M., & Al, P. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.04.030 · Cited by 157
Brown, W. V., Bays, H. E., Hassman, D. R., McKenney, J. M., Chitra, R., Hutchinson, H. G., & Miller, E. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129312 · Cited by 156
Bays, H. E., Dujovne, C. A., McGovern, M. E., White, T. E., Kashyap, M. L., Hutcheson, A. G., & Crouse, J. R. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00007-9 · Cited by 154
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.
Meads, C., Cummins, C., Jolly, K. B., Stevens, A. J., Burls, A., & Hyde (2000) · Health Technology Assessment · doi:10.3310/hta4230 · Cited by 152
Serum cholesterol concentration and death from suicide in men: Paris prospective study I
Zureik, M., Courbon, D., & Ducimetière, P. (1996) · BMJ · doi:10.1136/bmj.313.7058.649 · Cited by 152
The Economic Burden of Stroke in the United Kingdom
Youman, P., Wilson, K., Harraf, F., & Kalra, L. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321001-00005 · Cited by 152
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Chang, J. T., Staffa, J. A., Parks, M. A., & Green, L. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.977 · Cited by 151
Schneck, D. W., Knopp, R. H., Ballantyne, C. M., McPherson, R., Chitra, R., & Simonson, S. G. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02994-6 · Cited by 140
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini, S., Bon, G., Campbell, L., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., Sirtori, C., Egros, F., Fayyad, R., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06052-2 · Cited by 140
What role for statins? A review and economic model.
Ebrahim, S. B. J., Smith, G. D., McCabe, Payne, Pickin, Sheldon, T., Lampe, F. C., Sampson, F. C., Ward, S. E., & Wannamethee, S. G. (1999) · Health Technology Assessment · doi:10.3310/hta3190 · Cited by 139
Self-citationBritish National Formulary 1981
Vere, D. W. (1982) · Journal of the Royal College of Physicians of London · doi:10.1016/s0035-8819(25)02703-5 · Cited by 134
Gender bias in the diagnosis and treatment of coronary artery disease
Beery, T. A. (1995) · Heart & Lung · doi:10.1016/s0147-9563(95)80020-4 · Cited by 133
Mullen, M. J., Wright, D. J., Donald, A. E., Thorne, S., Thomson, H., & Deanfield, J. E. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00743-9 · Cited by 130
Paoletti, R., Fahmy, M. I., Mahla, G., Mizan, J., & Southworth, H. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800608 · Cited by 130
Koren, M. J., & Hunninghake, D. B. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.117 · Cited by 129
Joukhadar, C., Klein, N., Prinz, M., Schrolnberger, C., Vukovich, T., Wolzt, M., Dorner, G. T., & Schmetterer, L. F. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1612902 · Cited by 126
Sandercock, P. A., Berge, E., Dennis, M. S., Forbes, J., Hand, P. J., Kwan, J. S. K., Lewis, S. C., Lindley, R. I., Neilson, A. R., & Wardlaw, J. M. (2004) · Stroke · doi:10.1161/01.str.0000126871.98801.6e · Cited by 126
Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial
Liem, A. H., Boven, A. J. V., Veeger, N. J. G. M., Withagen, A. J. A. M., de Medina, R. M. R., Tijssen, J. G. P., & van Veldhuisen, D. J. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3291 · Cited by 126
Sacks, F. M., Pfeffer, M. A., Moyé, L. A., Brown, L. E., Hamm, P., Cole, T. G., HAWKINS, C. M., Braunwald, E., & The CARE Investigators (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90276-q · Cited by 125
Pravastatin, lipids, and atherosclerosis in the carotid arteries (plac-II)
Byington, R. P., Furberg, C. D., Crouse, J. R., Espeland, M. A., & Bond, M. G. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80471-8 · Cited by 124
Riegger, G. A. J., Abletshauser, C., Ludwig, M. Z., SCHWANDT, P., Widimsky, J., Jr., Weidinger, G., & Welzel, D. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00062-3 · Cited by 117
Frolkis, J. P., Pearce, G. L., Nambi, V., Minor, S., & Sprecher, D. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01303-7 · Cited by 113
Mehra, M. R., Uber, P. A., Vivekananthan, K., Solis, S., Scott, R. L., Park, M., Milani, R. V., & Lavie, C. J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02340-9 · Cited by 112
A Systematic Review of Health State Utility Values for Osteoporosis-Related Conditions
Brazier, J. E., Green, C., & Available, J. A. N. (2002) · Osteoporosis International · doi:10.1007/s001980200107 · Cited by 108
Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease
Serruys, P. W. J. C., Unger, F., & Sousa, F. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00418-4 · Cited by 108
Pickin, D. M., McCabe, C. J., Ramsay, L. E., Payne, N., Haq, I. U., Yeo, W. W., & Jackson, P. (1999) · Heart · doi:10.1136/hrt.82.3.325 · Cited by 108
Self-citationStein, E. A., Strutt, K., Southworth, H., Diggle, P. J., & Miller, E. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.009 · Cited by 106
Health‐related quality of life after myocardial infarction: an interview study
Roebuck, A., Furze, G., & Thompson, D. R. (2001) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2001.01809.x · Cited by 104
Salonen, R. M., Nyyssönen, K., Porkkala-Sarataho, E., & Salonen, J. T. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80468-8 · Cited by 104
Lacey, E. A., & Walters, S. J. (2003) · Journal of Epidemiology & Community Health · doi:10.1136/jech.57.8.622 · Cited by 104
Stewart, S. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3114 · Cited by 103
Events per person year—a dubious concept
Windeler, J., & Lange, S. (1995) · BMJ · doi:10.1136/bmj.310.6977.454 · Cited by 101
Ashraf, T., Hay, J. W., Pitt, B., Wittels, E. H., Crouse, J. R., Davidson, M. H., Furberg, C. D., & Radican, L. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00328-1 · Cited by 98
* (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80133-7 · Cited by 97
Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity
Chan, D. C., Watts, G. F., Mori, T. A., Barrett, P. H. R., Beilin, L. J., & Redgrave, T. G. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.01001.x · Cited by 96
Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
Wanner, C., for Die Deutsche Diabetes Dialyse Studie Investigators, Krane, V., Ruf, G., März, W., & Ritz, E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07158.x · Cited by 96
Tsevat, J., Kuntz, K. M., Orav, E. J., Weinstein, M. C., Sacks, F. M., & Goldman, L. (2001) · American Heart Journal · doi:10.1067/mhj.2001.114805 · Cited by 95
Indications for cholesterol-lowering medication: comparison of risk-assessment methods
Durrington, P. N., Prais, H., Bhatnagar, D., France, M. W., Crowley, V., Khan, J., & Morgan, J. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04027-6 · Cited by 94
Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?
Gaist, D., Rodríguez, L. A. G., Huerta, C., Hallas, J., & Sindrup, S. H. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000248 · Cited by 93
Transient Neurological Attacks in the General Population
Bots, M. L., van der Wilk, E. C., Koudstaal, P. J., Albert Hofman, D., & Grobbee, D. E. (1997) · Stroke · doi:10.1161/01.str.28.4.768 · Cited by 93
Atorvastatin and Thrombogenicity of the Carotid Atherosclerotic Plaque: the ATROCAP Study
Cofrancesco, E., Arbustini, E., Rossi, F., Negri, A., Tremoli, E., Gabrielli, L., Camera, M., & Cortellaro, M. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613151 · Cited by 92
Bosch, J. L., & Hunink, M. G. M. (2000) · Quality of Life Research · doi:10.1023/a:1008929129537 · Cited by 92
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
Colhoun, H. M., Thomason, M. J., Mackness, M., Maton, S., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J., & the CARDS Investigators (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00643.x · Cited by 92
Illingworth, D. R., Crouse, J. R., Hunninghake, D. B., Davidson, M., Escobar, I. D., Stalenhoef, A. F. H., Paragh, G., Ma, P. T. S., Liu, M., Melino, M. R., et al. (2001) · Current Medical Research and Opinion · doi:10.1185/03007990152005351 · Cited by 91
Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
Wardle, J., Armitage, J., Collins, R., Wallendszus, K., KEECH, A. C., & Lawson, A. (1996) · BMJ · doi:10.1136/bmj.313.7049.75 · Cited by 90
KEECH, A., COLLINS, R., MACMAHON, S., ARMITAGE, J., LAWSON, A., WALLENDSZUS, K., FATEMIAN, M., KEARNEY, E., LYON, V., MINDELL, J., et al. (1994) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060485 · Cited by 90
van Exel, J. N. A., Reimer, W. J. M. S. O., & Koopmanschap, M. A. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018496.02968.50 · Cited by 88
Blazing, M. A., de Lemos, J. A., Dyke, C. K., Califf, R. M., Bilheimer, D. W., & Braunwald, E. (2001) · American Heart Journal · doi:10.1067/mhj.2001.116959 · Cited by 88
Raison, J., Rudnichi, A., & Safar, M. E. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001470 · Cited by 88
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study
Tonkin, A. M., Colquhoun, D., Emberson, J., Hague, W. E., KEECH, A. C., Lane, G., MacMahon, S. W., Simes, R. J., Thompson, P. L., White, H. D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03257-8 · Cited by 87
Stein, D. T., Devaraj, S., Balis, D. S., ADAMS-HUET, B. A., & Jialal, I. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1201.100259 · Cited by 87
Kedward, J., & Dakin, L. (2003) · Europe PMC (PubMed Central) · Cited by 86
Statins and stroke: evidence for cholesterol-independent effects
Napoli, P. D., Taccardi, A. A., Oliver, M. F., & Caterina, R. D. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3236 · Cited by 85
Risk and Predictors of Stroke After Myocardial Infarction Among the Elderly
Lichtman, J. H., Krumholz, H. M., Wang, Y., Radford, M. J., & Brass, L. M. (2002) · Circulation · doi:10.1161/hc0902.104708 · Cited by 84
Soedamah‐Muthu, S. S. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00428-8 · Cited by 83
Lukkarinen, H., & Hentinen, M. (1997) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.1997.1997026073.x · Cited by 81
Pontrelli, L., Parris, W. E., Adeli, K., & Cheung, R. C. (2002) · Metabolism · doi:10.1053/meta.2002.30510 · Cited by 80
The West of Scotland Coronary Prevention Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015165 · Cited by 80
Comparative accuracy of cardiovascular risk prediction methods in primary care patients
Jones, A. F., Walker, J., Jewkes, C., Game, F. L., Bartlett, W. A., Marshall, T., & Bayly, G. R. (2001) · Heart · doi:10.1136/heart.85.1.37 · Cited by 79
Päivä, H., Laakso, J. T., Lehtimäki, T. J., Isomustajärvi, M., Ruokonen, I., & Laaksonen, R. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200302000-00010 · Cited by 77
Jm, V. D. A., Bredie, S. J. H., Sh, D., van Tits, L. J. H., Stalenhoef, A. F. H., & van Leusen, R. (2003) · Journal of Nephrology · doi:10.1093/joneph/16.2.238 · Cited by 77
Nanas, J. N., Alexopoulos, G. P., ANASTASIOU‐NANA, M. I., Karidis, K., Tirologos, A., Zobolos, S., Pirgakis, V., Anthopoulos, L., Sideris, D. A., Stamatelopoulos, S. F., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01025-1 · Cited by 76
Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?
van Hout, B. A., & Simoons, M. L. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2308 · Cited by 75
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD
Harris, K. P. G., Wheeler, D. C., Chong, C., & the Atorvastatin in CAPD Study Investigators (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00262.x · Cited by 74
Kinlay, S., Timms, T., Clark, M., Karam, C., Bilodeau, T., Ridker, P. M., Rifai, N., Carlson, W., Lloyd‐Jones, D. M., Johnstone, M. T., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02306-8 · Cited by 74
Golledge, J. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07421-7 · Cited by 73
Ito, H., Ouchi, Y., Ohashi, Y., Saito, Y., Ishikawa, T., Nakamura, H., & Orimo, H. (2001) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.8.33 · Cited by 73
Karalis, D. G., Ross, A. M., Vacari, R. M., Zarren, H. S., & Scott, R. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02337-2 · Cited by 72
Atorvastatin Increases ecNOS Levels in Human Platelets of Hyperlipidemic Subjects
Tannous, M., Cheung, R. M. C., Vignini, A., & Mutus, B. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614841 · Cited by 72
Huse, D. M., Russell, M. W., Miller, J. D., Kraemer, D. F., D’Agostino, R. B., Ellison, R. C., & Hartz, S. C. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00641-9 · Cited by 71
McManus, R. J., Mant, J., Meulendijks, C. F. M., Salter, R. A., Pattison, H. M., Roalfe, A. K., & Hobbs, F. D. R. (2002) · BMJ · doi:10.1136/bmj.324.7335.459 · Cited by 71
Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes
Grover, S. A., Coupal, L., Zowall, H., & Dorais, M. (2000) · Circulation · doi:10.1161/01.cir.102.7.722 · Cited by 68
Predicting CHD risk in patients with diabetes mellitus
Yeo, W. W., & Yeo, W. W. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00510.x · Cited by 67
Self-citationComaschi, M., & Menozzi, F. (2001) · PubMed · Cited by 67
Gentile, S., Turco, S., Guarino, G., Sasso, F. C., Amodio, M., Magliano, P. L., Salvatore, T., Corigliano, G., Agrusta, M., SIMONE, G. D., et al. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00106.x · Cited by 66
Johannesson, M. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2484 · Cited by 65
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In primary ASCVD prevention, the evidence indicates that generic statin-based treatments are cost-effective for people at least down to 1% annual total CVD risk and could be cost-effective at even lower risk,(589) with the highest tolerated statin dose likely the most costeffective.(591,593,594) Importantly, many pati…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.